“The adventure began in 1999, when IBSA brought the first product in the field of Human Reproduction to the Egyptian market. This was a field that the company had only recently began working in”, says Carmen Vigorelli. “That strategic launch was thanks to the intuition of Dr Licenziati (President & CEO of IBSA), who was the first to understand the opportunity that entering the Human Reproduction field in competition with pharmaceutical industry giants represented. In 1999, IBSA’s turnover on the Egyptian market was just 60,000 Swiss Francs. But two years later, in 2001, we achieved the first one million dollars. Habib staff, Dr Licenziati and IBSA staff met in Lugano. It was a real party atmosphere because we had opened up a new market”.
In collaboration with Habib HSO, IBSA now has a turnover of 25 million Swiss Francs in Egypt and a 55% market share, with local sales of 3 million ampoules of gonadotropins per year out of an annual IBSA production of 14 million ampoules. These figures put the Lugano pharmaceutical company among the top 4 gonadotropin producers in the world. The history of partnerships and successes between IBSA and Habib will continue in the coming years and will be enhanced by a new chapter, as two more products are soon to be launched on the Egyptian market. The pain and inflammation therapeutic area is also to be expanded. It was its privileged relationship with IBSA that launched HABIB HSO to the top of its local market. A relationship that is defined as ‘different’ to relationships the Egyptian distributor has with other companies. “What we have with IBSA,” confirms Saad Ibrahim, CEO of Habib HSO, “is a business relationship, but also a relationship of friendship based on mutual esteem and trust between people”.